{"id":"bucetin","rwe":[{"pmid":"37180350","year":"2023","title":"rac-N-(4-Eth-oxy-phen-yl)-3-hy-droxy-butanamide.","finding":"","journal":"IUCrData","studyType":"Clinical Study"},{"pmid":"8640751","year":"1996","title":"Reappraisal of eight representative carcinogenic and non-carcinogenic compounds in a new medium-term rat liver bioassay using D-galactosamine.","finding":"","journal":"Cancer letters","studyType":"Clinical Study"},{"pmid":"3479641","year":"1987","title":"Carcinogenicity of bucetin in (C57BL/6 X C3H)F1 mice.","finding":"","journal":"Journal of the National Cancer Institute","studyType":"Clinical Study"},{"pmid":"3821433","year":"1986","title":"Rare but serious risks associated with non-narcotic analgesics: clinical experience.","finding":"","journal":"Medical toxicology","studyType":"Clinical Study"},{"pmid":"4085048","year":"1985","title":"Mechanism of metabolic activation of the analgetic bucetin to bacterial mutagens by hamster liver microsomes.","finding":"","journal":"Chemical & pharmaceutical bulletin","studyType":"Clinical Study"}],"tags":[{"label":"bucetin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N02BE04","category":"atc"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BUCETIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:57:24.446169+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:57:30.293347+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUCETIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:57:30.638865+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1697856/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:31.342467+00:00"}},"allNames":"betadid","offLabel":[],"synonyms":["bucetin","(+/-)-Bucetin","betadid"],"timeline":[],"brandName":"Betadid","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"bucetin","explanation":"","oneSentence":"","technicalDetail":"Betadid is a small molecule that binds to a specific receptor or enzyme, altering its activity and leading to a downstream effect that produces the desired therapeutic outcome."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/413","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUCETIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:07:24.442805","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:32.954238+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"paracetamol","drugSlug":"paracetamol","fdaApproval":"1968-11-07","relationship":"same-class"}],"genericName":"bucetin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"paracetamol","brandName":"paracetamol","genericName":"paracetamol","approvalYear":"1968","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"6M7CVQ8PF8","CHEBI":"CHEBI:31311","INN_ID":"1283","UMLSCUI":"C0054195","chemblId":"CHEMBL1697856","ChEMBL_ID":"CHEMBL1697856","KEGG_DRUG":"D01116","DRUGBANK_ID":"DB13278","PUBCHEM_CID":"14130","MESH_SUPPLEMENTAL_RECORD_UI":"C023637"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":10,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"N02BE04","allCodes":["N02BE04","N02BE54","N02BE74"]},"biosimilarFilings":[],"recentPublications":[{"date":"2023 Mar","pmid":"37180350","title":"rac-N-(4-Eth-oxy-phen-yl)-3-hy-droxy-butanamide.","journal":"IUCrData"},{"date":"1996 Jun 24","pmid":"8640751","title":"Reappraisal of eight representative carcinogenic and non-carcinogenic compounds in a new medium-term rat liver bioassay using D-galactosamine.","journal":"Cancer letters"},{"date":"1987 Nov","pmid":"3479641","title":"Carcinogenicity of bucetin in (C57BL/6 X C3H)F1 mice.","journal":"Journal of the National Cancer Institute"},{"date":"1986","pmid":"3821433","title":"Rare but serious risks associated with non-narcotic analgesics: clinical experience.","journal":"Medical toxicology"},{"date":"1985 Jul","pmid":"4085048","title":"Mechanism of metabolic activation of the analgetic bucetin to bacterial mutagens by hamster liver microsomes.","journal":"Chemical & pharmaceutical bulletin"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:32.954238+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":false,"score":0}}